Simon Quick Advisors LLC Acquires Shares of 2,267 Masimo Corporation $MASI

Simon Quick Advisors LLC bought a new position in shares of Masimo Corporation (NASDAQ:MASI) during the second quarter, HoldingsChannel reports. The fund bought 2,267 shares of the medical equipment provider’s stock, valued at approximately $381,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Masimo by 0.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,371 shares of the medical equipment provider’s stock worth $1,894,000 after purchasing an additional 66 shares during the last quarter. Assetmark Inc. grew its stake in shares of Masimo by 5.0% in the second quarter. Assetmark Inc. now owns 1,539 shares of the medical equipment provider’s stock worth $259,000 after purchasing an additional 73 shares during the last quarter. Xponance Inc. boosted its position in Masimo by 1.1% during the first quarter. Xponance Inc. now owns 7,101 shares of the medical equipment provider’s stock valued at $1,183,000 after acquiring an additional 76 shares during the last quarter. Deutsche Bank AG boosted its position in Masimo by 1.5% during the first quarter. Deutsche Bank AG now owns 6,309 shares of the medical equipment provider’s stock valued at $1,051,000 after acquiring an additional 92 shares during the last quarter. Finally, State of Michigan Retirement System boosted its position in Masimo by 1.0% during the first quarter. State of Michigan Retirement System now owns 10,596 shares of the medical equipment provider’s stock valued at $1,765,000 after acquiring an additional 100 shares during the last quarter. Institutional investors own 85.96% of the company’s stock.

Masimo Trading Down 0.6%

MASI opened at $140.65 on Monday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.14 and a quick ratio of 1.61. Masimo Corporation has a fifty-two week low of $133.70 and a fifty-two week high of $194.88. The firm has a market capitalization of $7.64 billion, a PE ratio of -16.51 and a beta of 1.28. The company’s 50-day moving average is $144.80 and its 200 day moving average is $154.12.

Masimo (NASDAQ:MASI) last posted its earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 earnings per share for the quarter. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. The company had revenue of $617.00 million for the quarter. As a group, research analysts predict that Masimo Corporation will post 4.1 earnings per share for the current fiscal year.

Insider Activity at Masimo

In other Masimo news, Director William R. Jellison bought 3,000 shares of the business’s stock in a transaction dated Monday, August 11th. The shares were purchased at an average price of $145.98 per share, for a total transaction of $437,940.00. Following the purchase, the director directly owned 4,790 shares of the company’s stock, valued at approximately $699,244.20. This represents a 167.60% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 9.70% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have commented on MASI shares. Wall Street Zen raised shares of Masimo from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. BTIG Research reissued a “buy” rating and set a $198.00 price objective on shares of Masimo in a research report on Thursday, September 11th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Masimo in a research report on Wednesday, October 8th. Piper Sandler upped their price target on Masimo from $200.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 6th. Finally, Zacks Research downgraded Masimo from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 24th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $194.60.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.